Jamjoom Pharmaceuticals Factory Co.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. carries a market capitalization of 10.85B, placing it among publicly traded companies globally. Its enterprise value stands at 10.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jamjoom Pharmaceuticals Factory Co.'s next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. has 70.00M shares outstanding.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. trades at a trailing price-to-earnings ratio of 21.45. The price-to-sales ratio is 6.67, and the price-to-book ratio stands at 5.78.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. trades at an EV/EBITDA multiple of 18.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Jamjoom Pharmaceuticals Factory Co. trades at an EV/FCF ratio of 38.04, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 10.60B versus a market cap of 10.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. maintains a current ratio of 4.44, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.06, indicating moderate leverage, while an interest coverage ratio of 263.92 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jamjoom Pharmaceuticals Factory Co. posted a return on equity (ROE) of 29.55, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 28.65 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 23.84, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 29.47, useful for judging operating efficiency across full business cycles. The company generates approximately 1.46M in revenue per employee across its workforce of 1,117.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.52 indicates how many times Jamjoom Pharmaceuticals Factory Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jamjoom Pharmaceuticals Factory Co. recorded 31.17M in income tax expense. That works out to an effective tax rate of 5.80, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 537.11M, leaving 505.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Jamjoom Pharmaceuticals Factory Co.'s stock has declined approximately 23.93% over the past 52 weeks. The 50-day moving average sits at 132.75, while the 200-day moving average is 142.84.

Over the twelve months ended June 30, 2026, Jamjoom Pharmaceuticals Factory Co. generated 1.63B in revenue and converted that into 505.94M in net income, yielding earnings per share of 7.23. EBITDA reached 572.98M, while operating income came in at 526.79M.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. holds 266.40M in cash and equivalents against 20.00M in total debt, resulting in a net debt position of -265.82M. Total book value stands at 1.88B, with working capital of 1.19B providing operational flexibility.

Jamjoom Pharmaceuticals Factory Co. produced 349.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -72.96M in capital expenditures, free cash flow totaled 276.72M - equivalent to 3.95 per share.

Over the twelve months ended June 30, 2026, Jamjoom Pharmaceuticals Factory Co. posted a gross margin of 63.99, reflecting its pricing power and cost economics. The operating margin of 32.37 and net profit margin of 31.09 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Jamjoom Pharmaceuticals Factory Co. paid dividends of 2.00 per share. The dividend payout ratio of 27.67 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jamjoom Pharmaceuticals Factory Co. shareholders.

As of June 30, 2026, Jamjoom Pharmaceuticals Factory Co. has an Altman Z-Score of 16.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.